Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RAD52 | P43351 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitracrine SCHEMBL29399539 | 1.00 | HRH1 (1.00) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Nitracrine SCHEMBL1652148 | 0.99 | HRH1 (0.98) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Nitracrine SCHEMBL22587584 | 0.99 | HRH1 (0.98) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Nitracrine SCHEMBL2500143 | 0.99 | HRH1 (0.98) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Nitracrine SCHEMBL29711499 | 0.99 | HRH1 (0.98) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Nitracrine SCHEMBL1230044 | 0.98 | HRH1 (0.96) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Hydrochloric Acid SCHEMBL3341307 | 0.95 | HRH1 (0.90) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| Hydrochloric Acid SCHEMBL31237957 | 0.91 | HRH1 (0.83) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL7877715 | 0.90 | CHRM2 (0.80) | HRH1CHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL7877922 | 0.90 | CHRM2 (0.80) | HRH1CHRM2CHRM1DRD2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11221 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-12617897-B2 | Method for preparing multi-component polymers through post-polymerization modification | JIANGSU ZHONGLI GROUP CO., LTD. (CN) | 2026-05-05 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2002004030-A2 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2001097860-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097861-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001098294-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001080884-A1 | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2001060820-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000054795-A1 | COMBINED THERAPY WITH A CHEMOTHERAPEUTIC AGENT AND AN ONCOLYTIC VIRUS FOR KILLING TUMOR CELLS IN A SUBJECT | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |